Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Stoke Therapeutics (STOK) Leases (2022 - 2025)

Stoke Therapeutics has reported Leases over the past 4 years, most recently at $3.1 million for Q4 2025.

  • Quarterly results put Leases at $3.1 million for Q4 2025, down 28.63% from a year ago — trailing twelve months through Dec 2025 was $3.1 million (down 28.63% YoY), and the annual figure for FY2025 was $3.1 million, down 28.63%.
  • Leases for Q4 2025 was $3.1 million at Stoke Therapeutics, down from $3.7 million in the prior quarter.
  • Over the last five years, Leases for STOK hit a ceiling of $6.1 million in Q1 2024 and a floor of $3.1 million in Q3 2023.
  • Median Leases over the past 4 years was $4.3 million (2023), compared with a mean of $4.4 million.
  • Biggest five-year swings in Leases: plummeted 41.76% in 2023 and later skyrocketed 59.79% in 2024.
  • Stoke Therapeutics' Leases stood at $4.8 million in 2022, then dropped by 13.74% to $4.1 million in 2023, then rose by 5.98% to $4.3 million in 2024, then dropped by 28.63% to $3.1 million in 2025.
  • The last three reported values for Leases were $3.1 million (Q4 2025), $3.7 million (Q3 2025), and $3.2 million (Q2 2025) per Business Quant data.